Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LIFELINE SCIENTIFIC INC. We currently have 11 research reports from 1 professional analysts.
|08Dec16 04:58||RNS||CLOSING OF THE MERGER - CANCELLATION FROM AIM|
|10Nov16 07:00||RNS||Date of merger closing and cancellation|
|06Oct16 03:18||RNS||RESULTS OF SPECIAL MEETING|
|26Sep16 07:00||RNS||Half-year Report|
|14Sep16 05:13||RNS||Publication of Proxy Statement & Notice of Meeting|
|02Sep16 07:01||RNS||Recommended Cash Acquisition|
|02Sep16 07:00||RNS||Trading update|
Frequency of research reports
Research reports on
LIFELINE SCIENTIFIC INC
LIFELINE SCIENTIFIC INC
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Panmure Morning Note 26-09-2016
26 Sep 16
Following the company’s statement on 2 September 2016 (recommended cash acquisition, trading update) the company has issued interim results this morning. Given the ongoing process set in train following the announcement of the definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) (02 September 2016) we retain our recommendation and forecasts Under Review.
Panmure Morning Note 02-09-2016
02 Sep 16
This morning Lifeline Scientific has announced it has entered into a definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) and, separately, released a trading update for the 6 months ending 30 June 2016. The cash offer from SGM values Lifeline Scientific at circa $87.8m or $4.083 in cash per share. If approved the transaction is expected to close in the fourth quarter calendar 2016 and by no later than 9 December 2016. We remind investors that LSI is incorporated in the State of Delaware in the USA and the merger is proposed in accordance with the Delaware General Corporation Law. The acquisition is not subject to the UK City Code on Takeovers and Mergers and is subject to shareholder approval. We retain our recommendation and forecasts Under Review.
Panmure Morning Note 27-4-2016
27 Apr 16
FY15 headline numbers were highlighted in January’s trading update: revenues $39.4m, operating profit $5.7m (2014: $2.4m). Year-end cash $6.9m – company is now debt free having paid off revolver balance of $2.2m by year-end. Strategic review – company is in discussions with interested parties, which may or may not lead to an offer. Usual caveats on outcomes and timing apply, but given the Board expects to provide a further update by end June, we assume Lifeline is probably quite deep into the process and this looks like the lead in terms of possible strategic options.
Panmure Morning Note 19-01-16
19 Jan 16
Further to Lifeline's ahead-of-expectations trading update and announced stocking order ($3.3m) from its principal distributor in China (18 December 2015), the company has today released further detail on the year ending 31 December 2015. While the strategic and financial review announced on 21 September 2015 is still ongoing, strong operational progress is clearly being delivered and the confident tone of the statement is well-deserved. Prelims are expected by the end of April 2016.
Panmure Morning Note 18-12-15
18 Dec 15
This morning Lifeline Scientific announces an update on trading, in advance of a more detailed update scheduled for February, and the receipt of a stocking order from its principal distributor in China worth approximately US$3.3m. The company also announces that it expects revenues for the year ending 31 December 2015 to be ahead of expectations and for adjusted pre-tax profit to be materially ahead of market expectations. A further trading update will be provided in January.
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
10 for 17
09 Jan 17
As always at the start of a year, there are significant uncertainties about the year ahead but I think in 2017, the level of uncertainly has decisively moved up a gear. In fact, a leading economist at the LSE, Ethan Ilzetzki, was recently quoted as saying “I view the current global economic environment as the most uncertain in modern history”. Wow.